SLU-PP-332 Dosage Guide
The synthetic exercise mimetic. What the animal research shows, the oral-absorption problem, and the honest reason there is no established human dose.
In This Guide
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule nicknamed an exercise mimetic. It switches on a family of cell controls called estrogen-related receptors (ERRs), the same switches the body normally turns up during aerobic exercise. Flipping those switches boosts the cell machinery for energy and fat burning, which is why researchers describe it as mimicking some effects of exercise.
It is a research chemical, not a peptide, and not an approved medicine. It is grouped here with metabolic and weight-management research compounds because that is the space it is studied in, similar to how 5-Amino-1MQ is a non-peptide research compound covered alongside peptides.
Key Characteristics:
- Synthetic pan-ERR agonist: activates ERR-alpha, beta, and gamma, with the strongest effect on ERR-alpha
- Exercise mimetic: reproduces some cell-level effects of aerobic exercise in animals
- Small molecule, not a peptide: a designed chemical compound, not an amino-acid chain
- Preclinical only: tested in mice and cells, never in humans
- Poor oral absorption: given by injection in studies, a successor was built to fix the oral problem
- Not approved: a research chemical, not a regulated medicine
For the full mechanism and the studies behind it, see our SLU-PP-332 profile.
How SLU-PP-332 Works
When you do aerobic exercise, your cells turn up a set of master switches called estrogen-related receptors. These switches increase the number and activity of mitochondria, the energy plants inside cells, and ramp up fat burning. SLU-PP-332 turns those same switches on chemically, without the workout.
What that produced in animals
- More fat burning and less fat mass: obese mice given SLU-PP-332 burned more fat, used more energy, and lost fat mass
- Better insulin sensitivity: the same studies reported improved blood sugar handling
- More endurance: mice increased the endurance type of muscle fiber and ran longer
- Other organ effects: separate mouse studies reported benefits in heart failure and aging-kidney models, all tied to better mitochondrial function
What the Research Actually Shows
Here is the full published evidence base. Note that every entry is an animal or cell study. This is the honest state of the science.
| Study | Model | Finding |
|---|---|---|
| Discovery (2023) | Mice + muscle cells | Increased mitochondrial function, oxidative muscle fibers, and exercise endurance |
| Metabolic syndrome (2024) | Obese mice | Increased energy expenditure and fat burning, reduced fat mass, improved insulin sensitivity |
| Heart failure (2023) | Mice | Improved heart function and survival via better cardiac fat metabolism |
| Aging kidney (2023) | Aged mice | Reversed age-related kidney injury and inflammation, mimicking caloric restriction |
| Successor compound (2025) | Mice | Confirmed SLU-PP-332 lacks oral bioavailability, hence the orally active SLU-PP-915 |
Verified sources for SLU-PP-332
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Why There Is No Established Human Dose
A real dosage guide lists doses that come from human clinical trials. SLU-PP-332 has never been in a human trial, so there is no dose to list. We will not publish a milligram figure, because doing so would imply a level of evidence that does not exist.
- No human pharmacokinetics: how much reaches the bloodstream, how long it lasts, and how it is cleared in people are all unknown
- No dose-finding study: the studies that determine a safe and effective human dose have not been done
- Animal doses do not transfer: the milligram-per-kilogram amounts used in mice cannot be converted into a safe human dose without clinical research
The Oral Absorption Problem
This is the single most important practical fact about SLU-PP-332, and it is often left out of product marketing.
In the published research, SLU-PP-332 was given by injection, not by mouth, because it is poorly absorbed through the gut. The research group that created it went on to design a chemically different compound, SLU-PP-915, specifically because SLU-PP-332 lacks oral bioavailability. In other words, the scientists who made it concluded the oral version did not work well enough and built a replacement.
Forms & Sourcing
What is sold and what to know:
- Capsule form: research suppliers sell SLU-PP-332 as oral capsules, the form with the absorption concern above
- Powder form: also sold as a raw research powder for laboratory use
- No regulated product: there is no approved or standardized version, so strength and purity vary between sources
- For research use: it is sold as a research chemical, not for human consumption
SLU-PP-332 vs SLU-PP-915
SLU-PP-915 is the successor compound from the same research group. The comparison explains why it exists.
| Feature | SLU-PP-332 | SLU-PP-915 |
|---|---|---|
| Target | Pan-ERR agonist | Pan-ERR agonist |
| Oral absorption | Poor (given by injection) | Designed to be orally active |
| Exercise-mimetic activity (animal) | Yes | Yes, comparable |
| Human data | None | None |
Safety & Unknowns
- Unknown human side effects: the animal studies were not designed to map the side-effect profile a person would experience
- Broad metabolic action: because it changes energy metabolism across many tissues, the range of possible effects in humans is wide and uncharacterized
- No interaction data: how it behaves alongside medicines, other research compounds, or in people with existing conditions is unstudied
- Source quality risk: with no regulated product, purity and identity vary, adding a second layer of uncertainty on top of the unknown biology
Common SLU-PP-332 Misconceptions
Avoid these common errors in thinking about SLU-PP-332:
Frequently Asked Questions
Key Takeaways
- SLU-PP-332 is a synthetic exercise mimetic: it switches on the ERR pathway the body uses to adapt to aerobic exercise
- The evidence is animal-only: fat loss, endurance, and metabolic benefits were shown in mice, not humans
- There is no human dose: no clinical trial has established one, and we will not publish a milligram figure that does not exist
- The oral form is poorly absorbed: studies used injection, and a successor compound was built specifically to fix that
- No human safety data: risks in people are unknown
- It is a preclinical research chemical, not a peptide and not an approved medicine
This article is for educational and informational purposes only. See our Disclaimer.
References
- Billon C, et al. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” J Pharmacol Exp Ther. 2024;388(2):232-240. PubMed
- Billon C, et al. “Synthetic ERR Agonist Induces an ERR-alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.” ACS Chem Biol. 2023;18(4):756-771. PubMed
- Xu W, et al. “Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.” Circulation. 2023;149(3):227-250. PubMed
- Wang XX, et al. “Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.” Am J Pathol. 2023;193(12):1969-1987. PubMed
- Billon C, et al. “An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.” J Pharmacol Exp Ther. 2025;393(1):103787. PubMed
Next Steps
Continue your research with these resources.
5-Amino-1MQ Guide
Another non-peptide metabolic research compound, with its own dosing and evidence picture.
Read GuideBest Peptides for Weight Loss
How exercise mimetics compare with the better-evidenced weight-management compounds.
Read ArticlePeptide Directory
Browse every compound with research summaries and evidence ratings.
Open Directory